Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

3 results
Filters applied: . Clear all
Page 1
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH).
Flaherty KT, Gray RJ, Chen AP, Li S, McShane LM, Patton D, Hamilton SR, Williams PM, Iafrate AJ, Sklar J, Mitchell EP, Harris LN, Takebe N, Sims DJ, Coffey B, Fu T, Routbort M, Zwiebel JA, Rubinstein LV, Little RF, Arteaga CL, Comis R, Abrams JS, O'Dwyer PJ, Conley BA; NCI-MATCH team. Flaherty KT, et al. J Clin Oncol. 2020 Oct 13:JCO1903010. doi: 10.1200/JCO.19.03010. Online ahead of print. J Clin Oncol. 2020. PMID: 33048619
Four-Factor Score for Outcome of Ibrutinib Treatment in Chronic Lymphocytic Leukemia: Prognostic Model for Risk Group Definition.
Stilgenbauer S. Stilgenbauer S. J Clin Oncol. 2020 Oct 13:JCO2002685. doi: 10.1200/JCO.20.02685. Online ahead of print. J Clin Oncol. 2020. PMID: 33048620 No abstract available.
Newly Diagnosed High-Risk Prostate Cancer in an Era of Rapidly Evolving New Imaging: How Do We Treat?
Hussain M, Lin D, Saad F, Vapiwala N, Chapin BF, Sandler H, Evans CP, Carducci MA, Sachdev S. Hussain M, et al. J Clin Oncol. 2020 Oct 13:JCO2002268. doi: 10.1200/JCO.20.02268. Online ahead of print. J Clin Oncol. 2020. PMID: 33048621 No abstract available.
Feedback